Program
Ivermectin
Also written as “ivermectin”, “Ivermectin cream” and “CD5024”.
Its studies are mostly in Rosacea · COVID-19 · Lice Infestations · Dermatitis, Atopic · Acne Vulgaris, led by 14 companies.
Drug pageIvermectin: every studyMany companies study it; this page follows only the 28 they lead. All 163 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Galderma Groupits history only | 60 open or running | phase 4since Nov 24, 2015 | Dec 14, 2011 | none ahead |
| Johnson & Johnsonits history only | 40 open or running | phase 3since Jan 8, 2009 | Jan 8, 2009 | none ahead |
| Topaz Pharmaceuticalsits history only | 40 open or running | phase 3since Feb 8, 2010 | Oct 1, 2009 | none ahead |
| Humanis Saglık Anonim Sirketiits history only | 20 open or running | phase 1since Sep 13, 2021 | Sep 13, 2021 | none ahead |
| MedinCell S.Aits history only | 20 open or running | phase 2since Mar 28, 2022 | Oct 26, 2020 | none ahead |
| Sun Pharmaceutical Industriesits history only | 20 open or running | phase 1since May 3, 2017 | May 3, 2017 | none ahead |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Apr 18, 2021 | Apr 18, 2021 | none ahead |
| Infectopharm Arzneimittelits history only | 10 open or running | phase 3since Sep 28, 2021 | Sep 28, 2021 | none ahead |
| Insud Pharmaits history only | 10 open or running | phase 3since Aug 8, 2023 | Aug 8, 2023 | none ahead |
| Mayne Pharma International Ptyits history only | 10 open or running | phase 3since Oct 30, 2017 | Oct 30, 2017 | none ahead |
| Padagisits history only | 10 open or running | phase 3since Jun 6, 2016 | Jun 6, 2016 | none ahead |
| Teva Pharmaceutical Industriesits history only | 10 open or running | phase 3since Jul 19, 2016 | Jul 19, 2016 | none ahead |
| United Laboratoriesits history only | 10 open or running | phase 2since Sep 14, 2017 | Sep 14, 2017 | none ahead |
| Zydus Lifesciencesits history only | 10 open or running | phase 3since Sep 25, 2019 | Sep 25, 2019 | none ahead |
Also a collaborator on its studies: Eva Pharma and bioRASI.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 14 studies since Jan 8, 2009.
- Nov 21, 2016Phase 2 study in Acne VulgarisGalderma Group · NCT03034460 · 70 enrolled · Canada, France, Germany
- May 3, 2017Sun Pharmaceutical Industries’ first study: phase 1 study in Lice InfestationsNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT03257943 · 413 enrolled · United States
- Aug 11, 2017Phase 2 study in Dermatitis, AtopicGalderma Group · NCT03250624 · 63 enrolled · Canada
- Sep 14, 2017United Laboratories’ first study: phase 2 study in Pediculosis CapitisNew to United LaboratoriesUnited Laboratories · NCT03286101 · 120 enrolled · Philippines
- Oct 30, 2017Mayne Pharma International Pty’s first study: phase 3 study in Head LiceNew to Mayne Pharma International PtyMayne Pharma International Pty · NCT03337490 · 296 enrolled · United States
- Sep 25, 2019Zydus Lifesciences’ first study: phase 3 study in Facial RosaceaNew to Zydus LifesciencesZydus Lifesciences · NCT04106726 · 525 enrolled · United States
- Oct 26, 2020MedinCell S.A’s first study: phase 1 study in COVID-19New to MedinCell S.AMedinCell S.A · NCT04632706 · 24 enrolled · United Kingdom
- Apr 18, 2021Genuine Research Center, Egypt’s first study: phase 1 study in HealthyNew to Genuine Research Center, EgyptGenuine Research Center, Egypt · NCT04854460 · 30 enrolled · Egypt
- Sep 13, 2021Humanis Saglık Anonim Sirketi’s first study: phase 1 study in Anthelmintic AgentNew to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT05082753 · 50 enrolled · Jordan
- Sep 28, 2021Infectopharm Arzneimittel’s first study: phase 3 study in COVID-19New to Infectopharm ArzneimittelInfectopharm Arzneimittel · NCT05060666 · 412 enrolled
- Mar 28, 2022Phase 2 study in COVID-19MedinCell S.A · NCT05305560 · 400 enrolled · Bulgaria
- Aug 8, 2023Insud Pharma’s first study: phase 3 study in COVID-19New to Insud PharmaInsud Pharma · NCT05993143 · 249 enrolled · Spain
- Aug 14, 2024Phase 1 study in RosaceaHumanis Saglık Anonim Sirketi · NCT06557603 · 44 enrolled · India
- Aug 26, 2026Phase 1 study in RosaceaSun Pharmaceutical Industries · NCT07795567 · 865 enrolled · United States
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Glutamate-gated chloride channel modulator; Glutamate-gated chloride channel modulator”ChEMBL 37, by rule
Studies
All 28 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07795567Rosacea · United States | 1 | Completed | Sun Pharmaceutical Industries | Jun 24, 2026 | 865 |
| NCT06557603Rosacea · India | 1 | Completed | Humanis Saglık Anonim Sirketi | Jul 11, 2024 | 44 |
| NCT05993143COVID-19 · Spain | 3 | Terminated | Insud Pharma | Jul 21, 2021 | 249 |
| NCT05305560COVID-19 · Bulgaria | 2 | Completed | MedinCell S.A | Sep 15, 2022 | 400 |
| NCT05060666COVID-19 | 3 | UNKNOWN | Infectopharm Arzneimittel | Mar 2022 | 412 |
| NCT05082753Anthelmintic Agent · Jordan | 1 | Completed | Humanis Saglık Anonim Sirketi | Dec 21, 2020 | 50 |
| NCT04854460Healthy · Egypt | 1 | Completed | Genuine Research Center, Egypt | Feb 25, 2021 | 30 |
| NCT04632706COVID-19 · United Kingdom | 1 | Completed | MedinCell S.A | Mar 9, 2021 | 24 |
| NCT04106726Facial Rosacea · United States | 3 | Completed | Zydus Lifesciences | Aug 4, 2020 | 525 |
| NCT03337490Head Lice · United States | 3 | Completed | Mayne Pharma International Pty | Dec 4, 2017 | 296 |
| NCT03286101Pediculosis Capitis · Philippines | 2 | Completed | United Laboratories | Oct 12, 2017 | 120 |
| NCT03250624Dermatitis, Atopic · Canada | 2 | Completed | Galderma Group | Jun 26, 2017 | 63 |
| NCT03257943Lice Infestations · United States | 1 | Completed | Sun Pharmaceutical Industries | Jun 27, 2017 | 413 |
| NCT03034460Acne Vulgaris · Canada, France, Germany | 2 | Completed | Galderma Group | Nov 2, 2016 | 70 |
| NCT02840461Moderate to Severe Papulopustular Rosacea · United States | 3 | Completed | Teva Pharmaceutical Industries | Nov 2016 | 630 |
| NCT02795117Rosacea | 3 | Completed | Padagis | Feb 2017 | 486 |
| NCT02616250Rosacea · United States, Canada | 4 | Completed | Galderma Group | Sep 2016 | 190 |
| NCT01493947Rosacea · Bulgaria, Czech Republic, France and more | 3 | Completed | Galderma Group | Dec 2013 | 962 |
| NCT01494467Rosacea · United States, Canada | 3 | Completed | Galderma Group | Aug 2013 | 688 |
| NCT01493687Rosacea · United States, Canada | 3 | Completed | Galderma Group | Jul 2013 | 683 |
| NCT01068158Head Lice · United States | 3 | Completed | Topaz Pharmaceuticals | Jun 2010 | 371 |
| NCT01066585Head Lice · United States | 3 | Completed | Topaz Pharmaceuticals | Jun 2010 | 410 |
| NCT00994422Head Lice · United States | 2 | Completed | Topaz Pharmaceuticals | Dec 2009 | 264 |
| NCT00988533Head Lice · United States | 1 | Completed | Topaz Pharmaceuticals | Nov 2009 | 30 |
| NCT00921674Healthy | 1 | Completed | Johnson & Johnson | Apr 2005 | 24 |
| NCT00921219Healthy | 1 | Completed | Johnson & Johnson | Nov 2005 | 34 |
| NCT00921154Fasting · Ireland | 1 | Completed | Johnson & Johnson | May 2005 | 24 |
| NCT00819520Lice Infestations · France, Ireland, Israel and more | 3 | Completed | Johnson & Johnson | Sep 2004 | 812 |
How it is read
Names in the registry
- “Ivermectin”, 4 entries
- “ivermectin”, 4 entries
- “Ivermectin cream”, 2 entries
- “CD5024”, 2 entries
- “0.5% Ivermectin Cream”, 2 entries
Conditions, from the studies’ own filings
- Rosacea, 9 studies
- COVID-19, 4 studies
- Lice Infestations, 3 studies
- Dermatitis, Atopic, 1 study
- Acne Vulgaris, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.